1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Am J Obstet Gynecol 2002;187:116-26. PMID:
12114899
2. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-15. PMID:
17049716
3. Coyne KS, Sexton CC, Thompson CL, Milsom I, Irwin D, Kopp ZS, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the epidemiology of LUTS (EpiLUTS) study. BJU Int 2009;104:352-60. PMID:
19281467
4. Robertson C, Link CL, Onel E, Mazzetta C, Keech M, Hobbs R, et al. The impact of lower urinary tract symptoms and comorbidities on quality of life: the BACH and UREPIK studies. BJU Int 2007;99:347-54. PMID:
17313423
5. Lokeshwar SD, Harper BT, Webb E, Jordan A, Dykes TA, Jr DEN, et al. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Transl Androl Urol 2019;8:529-39. PMID:
31807429
6. Chughtai B, Forde JC, Thomas DDM, Laor L, Hossack T, Woo HH, et al. Benign prostatic hyperplasia. Nat Rev Dis Prim 2016;2:1-15.
7. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-9. PMID:
6206240
9. Haylen BT, De Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 2010;21:5-26. PMID:
19937315
10. Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 2011;108:1132-9. PMID:
21231991
11. Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, et al. EAU guidelines on the assessment of nonneurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2015;67:1099-109. PMID:
25613154
12. Chua ME, Mendoza J, See M, Esmena E, Aguila D, Silangcruz JM, et al. A critical review of recent clinical practice guidelines on the diagnosis and treatment of non-neurogenic male lower urinary tract symptoms. Can Urol Assoc J 2015;9:E463-70.
13. Deborah J. Lightner, Alexander Gomelsky LS and SPVF. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol 2019;202:558-63. PMID:
31039103
14. Black N. Patient reported outcome measures could help transform healthcare. BMJ 2013;346:1-5.
16. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, et al. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res 2010;19:539-49.
17. Lee JA, More SJ, Cotiw-an BS. Problems translating a questionnaire in a cross-cultural setting. Prev Vet Med 1999;41:187-94.
18. Wild D, Grove A, Eremenco S, McElroy S, Verjee-Lorenz A, Erikson P. Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR task force for translation and cultural adaptation. Value Heal 2005;8:94-104.
19. Cook DA, Beckman TJ. Current concepts in validity and reliability for psychometric instruments: theory and application 2006. Am J Med 2006;119:166 e7-16.
20. Donovan J, Abrams P, Peters T, Kay H, Reynard J, Chapple C, et al. The ICS-‘BPH’ Study: the psychometric validity and realibility of ICS male questionnaire. Br J Urol 1996;77:554-62. PMID:
8777617
21. Jackson S, Donovan J, Brookes S, Eckford S, Swithinbank L, Abrams P. The bristol female lower urinary tract symptoms questionnaire: development and psychometric testing. Br J Urol 1996;77:805-12. PMID:
8705212
22. Bright E, Cotterill N, Drake M, Abrams P. Developing and validating the international consultation on incontinence questionnaire bladder diary. Eur Urol 2014;66:294-300. PMID:
24647230
23. Oh SJ, Park HG, Lim SH, Hong SK, Martin ML, Ting BL, et al. Translation and linguistic validation of Korean version of the incontinence quality of life (I-QoL) instrument. J Korean Cont Soc 2002;6:10-23.
24. Oh SJ, Park HG, Paick SH, Park WH, Choo MS. Translation and linguistic validation of Korean version of the bristol female lower urinary tract symptom instrument. J Korean Cont Soc 2004;8:89-113.
25. Oh SJ, Park HG, Paick SH, Park WH, Choo MS. Translation and linguistic validation of Korean version of the King’s Health Questionnaire instrument. Korean J Urol 2005;46:438-50.
33. Kim DS, Chung BH. Translation validity and reliability of the Korean version of the DAN-PSS. Korean J Urol 2003;44:871-5.
34. Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002;11:563-74. PMID:
12206577
35. Coyne KS, Thompson CL, Lai JS, Sexton CC. An overactive bladder symptom and health-related quality of life short-form: validation of the OAB-q SF. Neurourol Urodyn 2015;34:255-63. PMID:
25783168
36. Acquadro C, Kopp Z, Coyne KS, Corcos J, Tubaro A, Choo MS. Translating overactive bladder questionnaires in 14 languages. Urology 2006;67:536-40.
37. Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M, et al. Symptom assessment tool for overactive bladder syndromeoveractive bladder symptom score. Urology 2006;68:318-23. PMID:
16904444
38. Homma Y, Gotoh M. Symptom severity and patient perceptions in overactive bladder: how are they related? BJU Int 2009;104:968-72.
40. Brookes ST, Donovan JL, Wright M, Jackson S, Abrams P. A scored form of the Bristol Female Lower Urinary Tract Symptoms questionnaire: data from a randomized controlled trial of surgery for women with stress incontinence. Am J Obstet Gynecol 2004;191:73-82. PMID:
15295345
41. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997;104:1374-9. PMID:
9422015
42. Okamura K, Nojiri Y, Osuga Y. Reliability and validity of the King’s Health Questionnaire for lower urinary tract symptoms in both genders. BJU Int 2009;103:1673-8. PMID:
19154505
43. Minassian VA, Sun H, Yan XS, Clarke DN, Stewart WF. The interaction of stress and urgency urinary incontinence and its effect on quality of life. Int Urogynecol J Pelvic Floor Dysfunct 2014;26:269-76.
44. Nixon A, Colman S, Sabounjian L, Sandage B, Schwiderski UE, Staskin DR, et al. A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol 2005;174:604-7.
45. Lee KS, Lee HW, Choo MS, Paick JS, Lee JG, Seo JT, et al. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the “propiverine study on overactive bladder including urgency data.”. BJU Int 2010;105:1565-70. PMID:
19912183
46. Notte SM, Marshall TS, Lee M, Hakimi Z, Odeyemi I, Chen WH, et al. Content validity and test-retest reliability of patient perception of intensity of urgency scale (PPIUS) for overactive bladder. BMC Urol 2012;12:1.
47. Cardozo L, Coyne KS, Versi E. Validation of the urgency perception scale. BJU Int 2005;95:591-6. PMID:
15705086
48. Wagner TH, Patrick DL, Bavendam TG, Martin ML, Buesching DP. Quality of life of persons with urinary incontinence: development of a new measure. Urology 1996;47:67-71. PMID:
8560665
50. Oh SJ, Son H, Kim SW. Psychometric properties of the korean version of the incontinence quality of life instrument in women with stress urinary incontiennce. J Korean Cont Soc 2009;13:51-60.
51. Vandoninck V, Van Balken MR, Agrò EF, Petta F, Caltagirone C, Heesakkers JPFA, et al. Posterior tibial nerve stimulation in the treatment of urge incontinence. Neurourol Urodyn 2003;22:17-23. PMID:
12478596
52. Avery K, Donovan J, Peters TJ, Shaw C, Gotoh M, Abrams P. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn 2004;23:322-30. PMID:
15227649
53. Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006;49:1079-86. PMID:
16460875
54. Pleil AM, Coyne KS, Reese PR, Jumadilova Z, Rovner ES, Kelleher CJ. The validation of patient-rated global assessments of treatment benefit, satisfaction, and willingness to continue - The BSW. Value Heal 2005;8 Suppl 1:S25-34
https://doi.org/10.1111/j.1524-4733.2005.00069.x.
56. Oh SJ, Choo MS, Kim HS, Kim JC, Lee JG, Yun JM, et al. Psychometric properties of the Korean version of the King’s health questionnaire in women with stress urinary incontinence. J Korean Cont Soc 2005;9:115-23.
57. Lim R, Liong ML, Leong WS, Yuen KH. Which outcome measures should be used in stress urinary incontinence trials? BJU Int 2018;121:805-10. PMID:
29319927
58. Gajewski JB, Schurch B, Hamid R, Averbeck M, Sakakibara R, Agrò EF, et al. An International Continence Society (ICS) report on the terminology for adult neurogenic lower urinary tract dysfunction (ANLUTD). Neurourol Urodyn 2018;37:1152-61. PMID:
29149505
59. Kennelly M, Thiruchelvam N, Averbeck MA, Konstatinidis C, Chartier-Kastler E, Trøjgaard P, et al. Adult neurogenic lower urinary tract dysfunction and intermittent catheterisation in a community setting: risk factors model for urinary tract infections. Adv Urol 2019;2019:2757862.
61. Lee Y, Kim E, Oh SJ, Lee BS, Kim DA. The linguistic validation and reliability of the Korean version ‘Qualiveen Questionnaire’. J Korean Acad Rehab Med 2010;34:524-43.
62. Welk B, Morrow S, Madarasz W, Baverstock R, Macnab J, Sequeira K. The validity and reliability of the neurogenic bladder symptom score. J Urol 2014;2-7.
63. Barry MJ, Cockett ATK, Holtgrewe HL, McConnell JD, Sihelnik SA, Winfield HN. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 1993;150:351-8. PMID:
7686980
64. Yalla SV, Sullivan MP, Lecamwasam HS, DuBeau CE, Vickers MA, Cravalho EG, et al. Correlation of American Urological Association symptom index with obstructive and nonobstructive prostatism. J Urol 1995;153:674-80.
65. Barry MJ. Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia. Urology 2001;58:25-32. PMID:
11750246
66. Koeveringe GA Van, Rademakers KLJ, Birder LA, Korstanje C. Detrusor underactivity: pathophysiological considerations, models and proposals for future research. ICI-RS 2013 Gommert 2014;33:591-6.
68. Kim M, Jung JH, Park J, Son H, Jeong SJ, Oh SJ, et al. Impaired detrusor contractility is the pathognomonic urodynamic finding of multiple system atrophy compared to idiopathic Parkinson’s disease. Park Relat Disord 2015;21:205-10.
69. Uren AD, Cotterill N, Harding C, Hillary C, Chapple C, Klaver M, et al. Qualitative exploration of the patient experience of underactive bladder. Eur Urol 2017;72:402-7. PMID:
28400168
70. Tarcan T, Rademakers K, Arlandis S, von Gontard A, van Koeveringe GA, Abrams P. Do the definitions of the underactive bladder and detrusor underactivity help in managing patients: International Consultation on Incontinence Research Society (ICI-RS) Think Tank 2017? Neurourol Urodyn 2018;37:S60-8. PMID:
30133789
71. Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan SA, Maggi M, et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2011;60:809-25. PMID:
21726934